Author

Shawn E. Jenjak

Medical College of WisconsinORCID 0000-0002-2142-334XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Assay:cryo-EM· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Brian F. VolkmaniD· 3 shared Andy ChevignéiD· 2 shared Joy DarcisiD· 2 shared Martine J. SmitiD· 2 shared Martyna SzpakowskaiD· 2 shared Roman R. SchlimgeniD· 2 shared Aashish ManglikiD· 1 shared Alexa De La Sancha· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

Brian F. VolkmanORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3

Maurice C.M.L. Buzink, Joy Darcis, Desislava Nesheva, Max Meyrath, Shawn Jenjak, Nilanjana Banerjee, Manisankar Ganguly, Ashna Reyaz, Ramanuj Banerjee, Esther A. Leliveld, Yong-Jun Kwon, Jerome Paggetti, Sybrand Zielhuis, Dick Pluim, Alwin Huitema, , Rob Leurs

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

bioRxiv · Nov 4, 2026 · PreprintMolecular Biology

Atypical GPCR Activation Resolved by Nanobody Engineering

Roman R. Schlimgen, Shawn E. Jenjak, Alexa De La Sancha, Joy Darcis, Christian Billesboelle, Linda J. Olson, Francis C. Peterson, Martine J. Smit, Aashish Manglik, Martyna Szpakowska, Andy Chevigné, Brian F. Volkman

This study reveals an unconventional activation mechanism of the atypical GPCR ACKR3 using engineered nanobodies and cryo-EM, showing that extracellular pocket volume changes, not microswitch conformational shifts, drive receptor activity.

bioRxiv · Jan 11, 2026 · PreprintBiochemistry

Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies

Claudia V. Perez Almeria, Omolade Otun, Roman R. Schlimgen, Thomas D Lamme, Lotte Di Niro, Caitrin Crudden, Jan Paul Bebelman, Noureldine Youssef, Lejla Musli, Shawn E. Jenjak, Vladimir Bobkov, Julia Drube, Carsten Hoffmann, Brian F. Volkman, Sébastien Granier, , Martine J. Smit

This study uses inverse agonistic nanobodies to reveal constitutive activity of ACKR3, showing it drives non-canonical signaling and basal cell motility, suggesting therapeutic potential.

Nature Communications · Dec 2, 2025Peer-reviewedBiochemistry